Clinical trial
Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for…
NCT00415285 · Georgia Center for Oncology Research & Education, Other · Unknown status
Key facts
| NCT number | NCT00415285 |
|---|---|
| Title | Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer |
| Official title | Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer |
| Lead sponsor | Georgia Center for Oncology Research & Education, Other |
| Collaborators | Sanofi Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine, Docetaxel/Capecitabine |
| Enrollment | 100 |
| Start date | Dec 1, 2006 |
| First posted | Dec 22, 2006 |
| Last update posted | Feb 13, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: